Compare AbbVie Inc (ABBV) vs Gartner Inc (IT) Price & Performance

AbbVie (ABBV) trades at $249.94, up 1.59% with bullish technical signals and strong analyst support. The company demonstrates solid revenue growth to $61.16B in 2025, though net margins have compressed to 6.9%. Recent quarterly earnings consistently beat expectations, with Q2 2026 EPS of $3.65 surpassing estimates. Technical indicators show bullish momentum with the current price near resistance at $249, while RSI suggests potential oversold conditions at lower timeframes.

AbbVie presents a compelling investment case with 71% analyst buy ratings and a $281.33 price target offering 12.6% upside. Key growth drivers include Skyrizi and Rinvoq offsetting Humira declines, though patent cliffs in the 2030s and regulatory risks require monitoring. The company's dividend growth streak and robust pipeline support long-term value, but investors should weigh execution risks against current valuation multiples.

Gartner (IT) trades at $185.6, up 0.42% today, with a bullish technical signal and strong earnings beats in recent quarters. The stock shows robust profitability with a 69.63% gross margin and 12% net income margin, though revenue growth has moderated. Recent news highlights Q2 2026 earnings exceeding expectations and raised full-year EPS guidance, driving positive investor sentiment.

Outlook is supported by valuation discounts (P/E 16.69) and high ROE (113.58%), but risks include consulting segment weakness and negative net cash flow trends. Analysts are mixed with a $172.80 consensus target, suggesting cautious optimism amid execution challenges.